A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma.
The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
The journal Blood has published a new study on a drug candidate for multiple myeloma, a form of cancer that affects about one per cent of all tumour patients, with some 600 people a year developing the disease in Sweden. Multiple myeloma is a life-threatening disease and there is a dire medical need for new therapies, especially for the patients whose tumour cells have become resistant to the conventional drugs.
“The discovery that our substance works on multiple myeloma cells resistant to conventional therapy is very promising for the future, says Professor Stig Linder at Karolinska Institutet’s Department of Oncology-Pathology. “We’re now very hopeful that we and our colleagues at Harvard Medical School will be able to develop an effective treatment.”
The study demonstrates that the drug candidate, called VLX1570, inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The exact mechanism of action of the substance was identified earlier at Karolinska Institutet (Nature Medicine, 2011). Put simply, the tumour cells can be said to be more sensitive than normal cells to disruption to the machinery that breaks down defective proteins. When this machinery is blocked, it triggers apoptosis (programmed cell death) in the tumour cells.
“We show that the drug candidate kills multiple myeloma cells from cancer patients,” says Professor Linder. “The substance is also effective against myeloma cells that have developed a resistance to the clinically used drug bortezomib.”
Dr Dharminder Chauhan at Harvard Medical School says that the mechanism of action is very interesting as regards the development of new cancer drugs and adds, “We’re delighted to be able to study the therapeutic potential of this new drug candidate in clinical studies. We hope that the joint research we’re doing will lead to improved cancer treatments.”
The study also found that the new substance could be combined synergistically with other cancer therapies. Karolinska Institutet and Harvard Medical School are due to launch a large-scale clinical study next year in association with drug discovery company Vivolux AB (Uppsala, Sweden).
“If the study proves successful it will represent a great step forward, mainly for all cancer patients but also for the Swedish drug industry,” says Professor Linder.
The Latest on: Cancer therapies
- Linda Nolan, 64, announces cancer has spread to her brain but remains ‘positive’ in light of new treatmenton March 27, 2023 at 12:38 am
One of her sisters joked that she now has some ‘nice wigs’ following her previous cancer treatment. Linda discovered that the cancer had spread to her brain after suffering three ‘quite nasty falls’, ...
- Novartis Shares Gain After Positive Breast-Cancer Trial Resultson March 27, 2023 at 12:27 am
By Cecilia Butini Shares in Swiss pharma major Novartis AG gained in early trading on Monday after the company reported positive trial data for ...
- Hypopharyngeal Cancer Treatment Market Growth By 2031on March 26, 2023 at 11:54 pm
The MarketWatch News Department was not involved in the creation of this content. Mar 26, 2023 (The Expresswire) -- The "Hypopharyngeal Cancer Treatment Market" Study Describes how the technology ...
- Novartis says Kisqali breast cancer drug cuts risk of recurrenceon March 26, 2023 at 11:17 pm
Novartis said on Monday that its Kisqali breast cancer drug had been shown to cut the risk of recurrence in women that were diagnosed at an early stage of the disease, a potential boost for the ...
- Thane man says Ayurveda centre cheated him of ₹15 lakh over wife's cancer treatment; 2 bookedon March 26, 2023 at 3:22 am
A railway employee has filed a cheating case against an Ayurvedic treatment centre. According to a Naupada police station official, the railway employee said the centre defrauded him of ₹15.22 lakh by ...
- When I Got Cancer, My Dreams Told Me What My Doctors Could Noton March 26, 2023 at 3:00 am
When all the rational decision-making options are bad, relying on dreams offers a different kind of logic that can be a lifesaver in its own way.
- Expert Advice On What Questions To Ask Your Doctor While Selecting A Treatment Plan For Breast Canceron March 25, 2023 at 6:00 am
You might not know what to ask your doctor when you're formulating a treatment plan for breast cancer. Health Digest spoke with an expert to get their advice.
- Time of day matters when it comes to cancer diagnosis and treatment, says metastasis studyon March 24, 2023 at 8:55 am
Your circadian rhythm doesn't just govern your sleeping schedule; it can also impact cancer development, diagnosis, and treatment. In a review paper published in the journal Trends in Cell Biology, ...
- Cancer: Time of day may matter for diagnosis, treatmenton March 24, 2023 at 8:15 am
Researchers from the Swiss Federal Institute of Technology have found circadian rhythm may also impact a person’s cancer diagnosis and treatment success. The body’s circadian rhythm — the natural ...
- Prostate cancer: New combination therapy could reduce progression riskon March 24, 2023 at 8:00 am
In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%.
via Bing News
The Latest on: Multiple myeloma
- Multiple Myeloma Therapeutics Market | Newsest Researchon March 26, 2023 at 7:39 pm
Complete Overview of the Global Multiple Myeloma Therapeutics Market: - Providing a complete overview of the global Multiple Myeloma Therapeutics market is a complex task, as there are many different ...
- This Cancer Drug Candidate Could Be a Hit for Pfizeron March 25, 2023 at 7:15 am
The FDA recently accepted the drugmaker's regulatory filing for review of a potential drug to treat a type of blood cancer.
- Global Multiple Myeloma Therapeutics Market In-Depth Analysis, Business Forecast, and Dynamics 2023 – 2030 By VMReportson March 24, 2023 at 10:56 am
Our Multiple Myeloma Therapeutics market report also provides detailed analysis on key segments and sub-segments of the market, enabling you to form a comprehensive picture of the industry. It covers ...
- Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myelomaon March 23, 2023 at 2:13 pm
A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.
- Multiple Myeloma Market to Exhibit a Remarkable Growth of USD 38.94 Billion by 2029, Size, Share, Trends, Key Drivers, Growth and Opportunity Analysison March 22, 2023 at 10:30 am
Data Bridge Market Research completed a qualitative study titled "Multiple Myeloma Market" with 100+ market data tables, pie charts, graphs, and figures spread across ...
- Cancer expert highlights advancements in treating multiple myelomaon March 20, 2023 at 9:42 am
March is Myeloma Awareness Month, and Sikander Ailawadhi, M.D., hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center, shares details about new ...
- Equitable Access to Multiple Myeloma Treatments Can Help Close the Survival Gapon March 20, 2023 at 4:47 am
Jennifer Flowers thought her pain and fatigue were a side effect of working out. Perhaps she’d pushed herself too hard or strained a muscle. But the pain persisted, so she scheduled an appointment ...
- Mayo Clinic Minute: What is multiple myeloma?on March 16, 2023 at 1:00 am
Multiple myeloma is a relatively uncommon form of blood cancer that affects less than 1% of the U.S. population, according the American Cancer Society. March is Myeloma Awareness Month. People younger ...
- The Information Patients Receive During Multiple Myeloma Treatment May Differ From What They Want to Knowon March 15, 2023 at 8:55 am
There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found.
- Video: What is multiple myeloma?on March 13, 2023 at 7:48 am
Multiple myeloma is a relatively uncommon form of blood cancer that affects less than 1% of the U.S. population, according the American Cancer Society.
via Bing News